Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Receivables: 2015-2024

Historic Receivables for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to $16.3 million.

  • Editas Medicine's Receivables rose 6352.38% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year increase of 136.01%. This contributed to the annual value of $16.3 million for FY2024, which is 59.67% up from last year.
  • Latest data reveals that Editas Medicine reported Receivables of $16.3 million as of FY2024, which was up 59.67% from $10.2 million recorded in FY2023.
  • Over the past 5 years, Editas Medicine's Receivables peaked at $16.3 million during FY2024, and registered a low of $267,000 during FY2021.
  • For the 3-year period, Editas Medicine's Receivables averaged around $10.5 million, with its median value being $10.2 million (2023).
  • Its Receivables has fluctuated over the past 5 years, first slumped by 95.59% in 2021, then surged by 1,826.97% in 2022.
  • Over the past 5 years, Editas Medicine's Receivables (Yearly) stood at $6.0 million in 2020, then slumped by 95.59% to $267,000 in 2021, then surged by 1,826.97% to $5.1 million in 2022, then spiked by 98.00% to $10.2 million in 2023, then skyrocketed by 59.67% to $16.3 million in 2024.